MedTrace Logo

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

NCT01724801 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2017-03-01

No results posted yet for this study

Summary

EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient with EGFR-mutant non-small cell lung cancer.

Conditions

  • Brain Metastasis
  • Non Small Cell Lung Cancer

Interventions

RADIATION

whole brain radiation(WBI)

WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles

DRUG

Icotinib

administered orally at a dose of 125 mg 3 times daily

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    collaborator OTHER

  • Guangdong Association of Clinical Trials

    lead OTHER

Principal Investigators

  • Jinji Yang, MD · Guangdong Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-14
Primary Completion
2015-06-30
Completion
2016-09-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01724801 on ClinicalTrials.gov